Table 2.
Clinical characteristics of 129 NPM1mut patients at diagnosis
| Variable | No. | % | |
|---|---|---|---|
| Age, years | |||
| Median | 54 | ||
| Range | 25–78 | ||
| Sex | |||
| Female | 64 | 50 | |
| Male | 65 | 50 | |
| AML history | |||
| De novo | 108 | 84 | |
| tAML | 2 | 2 | |
| Not available | 19 | 15 | |
| Cytogenetics | |||
| CN | 102 | 79 | |
| Deletion 9q | 5 | 4 | |
| Others | 3 | 2 | |
| Not available | 19 | 15 | |
| NPM1 mutation type | |||
| A | 100 | 78 | |
| B | 12 | 9 | |
| D | 9 | 7 | |
| Others | 8 | 6 | |
| WBC count, ×109/L | |||
| Median | 20 | ||
| Range | 1–279 | ||
| BM Blasts, % | |||
| Median | 80 | ||
| Range | 20–100 | ||
| Induction cycles, n | |||
| 1 | 16 | 12 | |
| 2 | 113 | 88 | |
| Remission status after first induction cycle (n = 129) | |||
| CR/CRi | 97 | 75 | |
| PR | 31 | 24 | |
| RD | 1 | 1 | |
| Remission status after second induction cycle (n = 113) | |||
| CR | 112 | 87 | |
| Relapse | 1 | 1 | |
| Consolidation therapy (n = 127) | |||
| High-dose Cytarabine | 114 | 88 | |
| Allogeneic SCT | 9 | 7 | |
| Autologous SCT | 4 | 3 | |
| Overall survival, days | |||
| Median | 535 | ||
CN cytogenetically normal, WBC white blood cell, BM bone marrow, CR complete remission, CRi complete remission with incomplete hematologic recovery, PR partial remission, RD refractory disease, SCT stem cell transplantation